截至发稿，安图生物市值为221亿元。 每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ （记者 王晓波） 每经AI快讯，安图生物（SH 603658，收盘价：38.66元）10月29日晚间发布公告称，公司第五届第八次 董事会会议于2025年10月28日在公司会议室以现场和通讯相结合的方式召开。会议审议了《关于修订 < 公司章程> 暨取消监事会、设置职工代表董事的议案》等文件。 2024年1至12月份，安图生物的营业收入构成为：体外诊断占比98.17%，其他业务占比1.83%。 ...

Company Performance - Antu Biology reported a revenue of approximately 3.127 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 7.48% [1] - The net profit attributable to shareholders was about 860 million yuan, down 10.11% year-on-year [1] - Basic earnings per share were 1.5 yuan, reflecting a decrease of 9.09% compared to the previous year [1] Market Overview - As of the report, Antu Biology's market capitalization stood at 22.1 billion yuan [2] - The A-share market has surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2]

郑州安图生物工程股份有限公司 2025 年第三季度报告 证券代码：603658 证券简称：安图生物 郑州安图生物工程股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 基本每股收益（元/股） | 0.50 | -15.25 | 1.50 | -9.09 | | --- | --- | --- | --- | --- | | 稀释每股收益（元/股） | 0.50 | -15.25 | 1.50 | -9.09 | | 加权平均净资产收益率 | 3.35 | 减少 0.67 | 9.86 | 减少 1.2 个百 | | （%） | | 个百分点 | | 分点 | | | 本报告期末 | | 上年度末 | 本报告期末比 上年度末增减 | | | | | | 变动幅度(%) | | 总资产 | 11,726,944,829.70 | | 11,875,065,943.97 | -1.25 | | 归属于上市公司股东的 所有者权益 | 8,746,504,579.10 | | 8, ...

郑州安图生物工程股份有限公司 章 程 二〇二五年 10 月 | 第一章 | 总 则 | | 2 | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 | | 3 | | 第三章 | 股份 | | 3 | | 第一节 | 股份发行 | | 3 | | 第二节 | | 股份增减和回购 | 4 | | 第三节 | 股份转让 | | 6 | | 第四章 | 股东和股东会 | | 6 | | 第一节 | 股东 | | 6 | | 第二节 | | 控股股东和实际控制人 | 9 | | 第三节 | | 股东会的一般规定 | 10 | | 第四节 | | 股东会的召集 | 14 | | 第五节 | | 股东会的提案与通知 | 15 | | 第六节 | | 股东会的召开 | 17 | | 第七节 | | 股东会的表决和决议 | 19 | | 第五章 | 董事会 | | 23 | | 第一节 | 董事 | | 23 | | 第二节 | 董事会 | | 27 | | 第三节 | 独立董事 | | 32 | | 第四节 | | 董事会专门委员会 | 34 | | 第六章 | 高级管理人员 | | 3 ...

Group 1 - The "Listing Company Hainan Tour" event, part of the "Enterprise Navigation" initiative, was launched on October 25 and will last for four days, focusing on key industries such as healthcare, finance, information technology, and electronic manufacturing [1][4]. - Hainan Free Trade Port is attracting more listed companies due to its unique policy advantages and industrial appeal, as highlighted by Yang Zengli, the Party Secretary of Antu Biotech [3][4]. - Antu Biotech, the first listed in vitro diagnostic R&D and manufacturing company in China, has taken its first step in investing in Hainan, aiming to leverage the Free Trade Port's policy advantages for building a "China R&D" hub [4]. Group 2 - Antu Biotech's product range includes immunology, microbiology, biochemistry, molecular diagnostics, and coagulation, with ongoing expansion into sequencing, mass spectrometry, and smart laboratory technologies [4]. - Yang Zengli emphasized the impressive open atmosphere and industrial clustering effect since the establishment of Hainan Free Trade Port, particularly noting the Boao Lecheng International Medical Tourism Pilot Zone's advantages in "licensed drug and device" usage and "zero tariff" policies [4]. - The company has invested in the first government investment fund focused on biomedicine in the Free Trade Port, planning to further develop R&D and industrialization projects, including establishing an innovative product pilot base and reagent manufacturing center [4]. Group 3 - Yang Zengli expressed optimism about the upcoming full closure operation of Hainan Island, which is expected to bring cross-border circulation and cost advantages, allowing the company to export in vitro diagnostic reagents as "Hainan-made" products to Southeast Asia [4]. - Antu Biotech aims to actively connect with local medical institutions and research platforms during the "Listing Company Hainan Tour" to explore specific cooperation paths, anticipating a dual interaction between policy and practice to accelerate local innovative technologies [4].

（文章来源：证券日报） 证券日报网讯 10月24日晚间，安图生物发布公告称，公司于近日收到招商证券股份有限公司（简称"招 商证券"）出具的《关于更换保荐代表人的函》。招商证券为公司2019年公开发行可转换公司债券和 2020年非公开发行股票的保荐人，原指派的保荐代表人为刘海燕、鄢坚。现因刘海燕同志近期职务调 动，不再适合继续履行公司2019年公开发行可转换公司债券和2020年非公开发行股票项目的募集资金专 项持续督导职责。为此，招商证券决定指派张茜同志自2025年10月22日起接替刘海燕同志履行公司2019 年公开发行可转换公司债券和2020年非公开发行股票项目的剩余督导期的保荐工作事宜。 ...

郑州安图生物工程股份有限公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 日收到招商证券股份有限公司（以下简称"招商证券"）出具的《关于更换保荐 代表人的函》。 招商证券为公司2019年公开发行可转换公司债券和2020年非公开发行股票 的保荐人，原指派的保荐代表人为刘海燕、鄢坚。现因刘海燕同志近期职务调动， 不再适合继续履行公司2019年公开发行可转换公司债券和2020年非公开发行股 票项目的募集资金专项持续督导职责。为此，招商证券决定指派张茜同志自2025 年10月22日起接替刘海燕同志履行公司2019年公开发行可转换公司债券和2020 年非公开发行股票项目的剩余督导期的保荐工作事宜。 本次变更后，公司2019年公开发行可转换公司债券和2020年非公开发行股票 持续督导保荐代表人为鄢坚同志和张茜同志。 证券代码：603658 证券简称：安图生物 公告编号：2025-068 公司董事会对刘海燕同志在担任保荐代表人期间所做的工作表示 ...

Core Viewpoint - The establishment of the Hainan Free Trade Port is expected to enhance companies' access to global R&D resources and deepen international cooperation, particularly benefiting enterprises like Antu Biology in the medical diagnostics sector [1]. Group 1: Company Overview - Antu Biology, listed on the Shanghai Stock Exchange in 2016, is the first publicly traded company in China's in vitro diagnostics sector, focusing on various testing fields including immunology and molecular diagnostics [2]. - The company aims to leverage Hainan's policies in "medical health + technological innovation" to align with its strategic goals [2]. Group 2: Policy Advantages - Key policy advantages include the "special drug and device" policy in the Boao Lecheng International Medical Tourism Pilot Zone, the "zero tariff" benefits of the free trade port, and support for real-world data applications [2]. - Since 2024, 34 batches of medical devices have benefited from tariff exemptions exceeding 8 million yuan, significantly reducing the cost of importing core components for the company [2]. Group 3: Collaboration Opportunities - Three major collaboration opportunities identified include: 1. R&D transformation opportunities through the full-chain service model in the Lecheng Pilot Zone, which can accelerate clinical validation and technology transfer for Antu's high-throughput detection products [3]. 2. Production collaboration opportunities through the "Lecheng R&D + Haikou production" model, facilitating localized production of imported medical devices [3]. 3. Market expansion opportunities driven by the international medical tourism positioning of the Lecheng Pilot Zone, which aligns with the demand for upgraded grassroots medical services in Hainan [3]. Group 4: Investment Initiatives - Antu Biology has initiated its investment strategy by participating in the Haikou National High-tech Zone Innovation Fund, which focuses on biomedicine and has raised 160 million yuan in collaboration with state-owned enterprises [3]. - Future plans include establishing an innovation product pilot base and a reagent manufacturing center to promote "Hainan manufacturing" on the international stage [3]. Group 5: Future Expectations - The upcoming full closure of the Hainan Free Trade Port is viewed as a new opportunity for companies to develop, with expectations to connect with local medical institutions and research platforms for potential technological collaborations [4]. - Confidence in Hainan's ecosystem is bolstered by previous experiences with the Haikou National High-tech Zone Innovation Fund and successful practices within the Lecheng Pilot Zone [5].

Core Points - The company announced the redemption of a structured deposit worth 10 million yuan from Industrial Bank [1] - The decision was made during the board and supervisory meetings held on December 11, 2024, allowing the use of idle raised funds for cash management [1] - The company plans to use up to 1.7 billion yuan from public convertible bonds and 17 billion yuan from private stock issuance for cash management in safe and liquid financial products [1] Redemption Details - On May 28, 2025, the company purchased a large deposit of 10 million yuan using idle funds from a private stock issuance [2] - The deposit matured on October 19, 2025, yielding an interest income of 130,200 yuan, which was returned to the fundraising account on October 20, 2025 [2] Fund Management Overview - The company has been actively managing idle raised funds over the past twelve months, focusing on high-security and liquid financial products [3]

证券代码：603658 证券简称：安图生物 公告编号：2025-067 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次使用闲置募集资金进行现金管理赎回的情况 2025 年 05 月 28 日，公司通过兴业银行郑州商务外环路支行使用非公开发行股 票闲置募集资金购买大额存单 1,000 万元。上述大额存单已于 2025 年 10 月 19 日到 期，公司收到到期本金人民币 1,000 万元，获得利息收益人民币 13.02 万元。上述大 额存单本金和收益于 2025 年 10 月 20 日归还至募集资金账户。 1 本次赎回产品名称：兴业银行可转让单位大额存单 本次赎回金额：1,000 万元 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"） 于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次 会议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同 意公司在确保不影响募集资金投资项 ...